DNA methylation signature predicting bevacizumab efficacy in metastatic breast cancer
Gampenrieder, SP; Rinnerthaler, G; Pulverer, W; Weinhusel, A; Hufnagl, C; Hackl, H; Hauser-Kronberger, C; Mlineritsch, B; Greil, R CANCER RES. 2017; 77:
TIGIT as a new target for checkpoint inhibition for chronic lymphocytic leukemia
Catakovic, K; Gassner, F; Rathswohl, C; Greil, R; Hartmann, T; Geisberger, R LEUKEMIA LYMPHOMA. 2017; 58: 53-54.
Casein Kinase 1 delta/epsilon inhibition blocks CLL chemotaxis and delays leukemia onset in the E mu-TCL1 mouse model of chronic lymphocytic leukemia
Janovska, P; Verner, J; Kohoutek, J; Bryjoval, L; Dzimkova, M; Skabrahova, H; Radaszkiewicz, T; Nemcova, T; Hoferova, Z; Vasickova, K; Smyckova, L; Gregorova, M; Egle, A; Pavlova, S; Poppova, L; Pospisilova, S; Bryja, V LEUKEMIA LYMPHOMA. 2017; 58: 210-211.
R-EFECT: A multicenter, retrospective evaluation of CML therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting
Petzer, A; Herndlhofer, S; Weltertnann, A; Sliwa, T; Schmidt, S; Greil, R; Wolfler, A; Wiesholzer, M; Dormann, C; Thaler, J; Tinchon, C; Ruckser, R; Lang, A; Hanig, J; Winiger, I; Muenchmeier, N; Sperr, WR ONCOL RES TREAT. 2017; 40: 58-58.
INSIDE-OUT VLA-4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49D: CLINICAL RELEVANCE
Tissino, E; Benedetti, D; Herman, SE; ten Hacken, E; Ahn, IE; Chaffee, KG; Rossi, FM; Dal Bo, M; Bulian, P; Bomben, R; Bayer, E; Harzschel, A; Gutjahr, JC; Postorino, M; Santinelli, E; Ayed, A; Zaja, F; Chiarenza, A; Chigaev, A; Sklar, LA; Burger, JA; Ferrajoli, A; Shanafelt, TD; Wiestner, A; Del Poeta, G; Hartmann, TN; Gattei, V; Zucchetto, A HAEMATOLOGICA. 2017; 102: 229-229.
NGS ANALYSIS OF 474 BONE MARROW SAMPLES FROM 157 AML PATIENTS TREATED WITH AZACITIDINE-IMPACT OF AGE ON MUTATIONAL LOAD
Pleyer, L; Gassner, FJ; Burgstaller, S; Wedler, H; Hartmann, TN; Jansko, B; Neureiter, D; Thaler, J; Greil, R HAEMATOLOGICA. 2017; 102: 215-216.
Low expression of miR-20a-5p predicts benefit to bevacizumab in metastatic breast cancer patients treated within the TANIA trial
Gampenrieder, SP; Rinnerthaler, G; Hackl, H; Steiner, M; Fuentes, CM; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Greil, R ANN ONCOL. 2017; 28:
Real life registry data of primary localisation of a well-defined colon cancer population of western Austria (Salzburg, Tyrol and Vorarlberg), eastern Switzerland (St. Gallen and Graubunden) and Liechtenstein
Hartmann, BL; Oberaigner, W; Frick, H; Weiss, L; Winder, T; Philipp-Abbrederis, K; Herrmann, C; Huynh, MQ; Spizzo, G; Lang, CM; Seeber, A; Schneider, J; Woll, E; Mosler, P; Greil, R; Rossle, M; Rumpold, H; Gastl, G; von Moos, R; Lang, AH ANN ONCOL. 2017; 28:
CTCA toxicity scoring and EORTC quality of life questionnaire: A comparison of physiciansxxx and patientsxxx scoring of toxicity in the „Panther trial“
Brandberg, Y; Loibl, S; Foukakis, T; Johansson, H; Gnant, M; Singer, CF; von Minckwitz, G; Bengtsson, NO; Karlsson, E; Mlineritsch, B; Hellstrom, M; Steger, G; Carlsson, L; Egle, D; Greil, R; Bergh, J ANN ONCOL. 2017; 28:
Quality-of-life results from a randomized, phase-II-study of the therapeutic cancer vaccine L-BLP25 (Stimuvax (R)) in the preoperative treatment of women with primary breast cancer (ABCSG-34)
Bjelic-Radisic, V; Singer, CF; Pfeiler, G; Hubalek, M; Bartsch, R; Stoger, H; Pichler, A; Petru, E; Greil, R; Wette, V; Petzer, A; Sevelda, P; Egle, D; Dubsky, P; Fitzal, F; Jakesz, R; Balic, M; Frantal, S; Solkner, L; Gnant, M ANN ONCOL. 2017; 28: